Anti-CDKL5 Antibody, clone 2J15 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 2J15 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects Cyclin-dependent kinase-like 5 (CDKL5). It targets an epitope within 23 amino acids in the C-terminal half.

KLH-conjugated linear peptide corresponding to 23 amino acids within the C-terminal half of Human Cyclin-dependent kinase-like 5 (CDKL5).

Quality Control Testing

Evaluated by Western Blotting in HeLa cell lysate.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected CDLK5 in in HeLa cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected CDKL5 in lysate from Mouse brain tissue and 1:10,000 in Rat brain tissue.

Affinity Binding Assay: A representative lot of this antibody bound CDKL5 peptide with a KD of 5.6 x 10-9 in an affinity binding assay.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected CDKL5 in Human colon tissue sections.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected CDKL5 in HeLa cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Cyclin-dependent kinase-like 5 (UniProt: O76039) is encoded by the CDKL5 gene also known as STK9 (Gene ID: 6792) in human. It is a Serine/Threonine-protein kinase that mediates phosphorylation of MECP2. The Primary structure of Cyclin-dependent kinase-like 5 protein consists of an N-terminal catalytic domain, including the TEY sequence observed in MAPK family kinases, a C-terminal regulatory domain, two nuclear localization signal (NLS) sequences and a nuclear export signal (NES). Subcellular localization of cyclin-dependent kinase-like 5 is regulated through phosphorylation by DYRK1A on Ser-308 residue near the NLS (amino acids 312 315). As a result, the protein is exported to the cytoplasm. High expression of Cyclin-dependent kinase-like 5 protein is observed either in the nucleus or in the cytoplasm in various brain areas and developmental stages. It plays a role in brain development, neuronal maturation and migration, and synapse formation among others. Mutations or chromosomal translocations in the CDKL5 gene are associated with neurodevelopmental disorders like Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) and developmental and epileptic encephalopathy 2, and found in patients manifesting a severe form of epilepsy, early-onset seizures, mental retardation and in West syndrome. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Oi, A., et al., (2017) Biochem. Biophys. Res. Commun. 482(2); 239-245; Katayama, S., et al., (2020) Neural Plast. 2020; 6970190; Yong-Chuan Zhu, Y-C., and Xiong, Z-Q. (2019). Dev. Neurobiol. 79(1); 8-19; L. Rusconi, L., t al., (2008) JBC 283(44); 30101-30111).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.